{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T05:53:10Z","timestamp":1771653190515,"version":"3.50.1"},"reference-count":25,"publisher":"Informa UK Limited","issue":"8","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Leukemia & Lymphoma"],"published-print":{"date-parts":[[2015,8,3]]},"DOI":"10.3109\/10428194.2014.994205","type":"journal-article","created":{"date-parts":[[2015,1,7]],"date-time":"2015-01-07T07:03:47Z","timestamp":1420614227000},"page":"2309-2314","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":27,"title":["Real-life comparison of severe vascular events and other non-hematological complications in patients with chronic myeloid leukemia undergoing second-line nilotinib or dasatinib treatment"],"prefix":"10.1080","volume":"56","author":[{"given":"Joanna","family":"Gora-Tybor","sequence":"first","affiliation":[{"name":"Institute of Hematology and Transfusion Medicine, Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ewa","family":"Medras","sequence":"additional","affiliation":[{"name":",","place":["Poland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malgorzata","family":"Calbecka","sequence":"additional","affiliation":[{"name":",","place":["Poland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnieszka","family":"Kolkowska-Le\u015bniak","sequence":"additional","affiliation":[{"name":"Institute of Hematology and Transfusion Medicine, Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edyta","family":"Ponikowska-Szyba","sequence":"additional","affiliation":[{"name":",","place":["Poland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadeusz","family":"Robak","sequence":"additional","affiliation":[{"name":",","place":["Poland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krzysztof","family":"Jamroziak","sequence":"additional","affiliation":[{"name":"Institute of Hematology and Transfusion Medicine, Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2015,3,5]]},"reference":[{"key":"e_1_3_2_2_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2010.07.001"},{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062867"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055229"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.84"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055104"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-03-080689"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S19901"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.2147\/BTT.S50734"},{"key":"e_1_3_2_10_1","first-page":"1395","article-title":"Severe adverse events associated with the use of second-line BCR\/ABL tyrosine kinase inhibitors: preferential occurrence in patients with comorbidities","volume":"96","author":"Valent P","year":"2011","unstructured":"Valent P. Severe adverse events associated with the use of second-line BCR\/ABL tyrosine kinase inhibitors: preferential occurrence in patients with comorbidities. Haematologica 2011;96:1395\u20131397.","journal-title":"Haematologica"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djr292"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.69"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2012.04.005"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.70"},{"key":"e_1_3_2_15_1","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1182\/blood.V122.21.92.92","article-title":"ENESTnd update: nilotinib (NIL) vs imatinib (IM) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) and the impact of early molecular response (EMR) and Sokal risk at diagnosis on long-term outcomes","volume":"122","author":"Hochhaus A","year":"2013","unstructured":"Hochhaus A, Hughes TP, Clark RE et al. ENESTnd update: nilotinib (NIL) vs imatinib (IM) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) and the impact of early molecular response (EMR) and Sokal risk at diagnosis on long-term outcomes. Blood 2013;122(Suppl. 1): Abstract 92.","journal-title":"Blood"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"e_1_3_2_17_1","first-page":"342","article-title":"Reversible pulmonary hypertension as a consequence of dasatinib treatment in a patient with chronic myeloid leukemia and scleroderma","volume":"34","author":"Ryczek R","year":"2013","unstructured":"Ryczek R, G\u00f3ra-Tybor J, Betkier-Lipi\u0144ska K, et al. Reversible pulmonary hypertension as a consequence of dasatinib treatment in a patient with chronic myeloid leukemia and scleroderma. Pol Merkur Lekarski 2013;34:342\u2013344.","journal-title":"Pol Merkur Lekarski"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.3087"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2010.10.017"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-07-102061"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-10-532341"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-08-376087"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07108.x"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.0329"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm049486a"},{"key":"e_1_3_2_26_1","unstructured":"NCCN Clinical Practice Guidelines in Oncology. Chronic myeloid leukemia v. 1.2015. Available from: www.nccn.org"}],"container-title":["Leukemia & Lymphoma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.3109\/10428194.2014.994205","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T12:23:25Z","timestamp":1770899005000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.3109\/10428194.2014.994205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,5]]},"references-count":25,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2015,8,3]]}},"alternative-id":["10.3109\/10428194.2014.994205"],"URL":"https:\/\/doi.org\/10.3109\/10428194.2014.994205","relation":{},"ISSN":["1042-8194","1029-2403"],"issn-type":[{"value":"1042-8194","type":"print"},{"value":"1029-2403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,5]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2014-08-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-11-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-03-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}